Equity Overview
Price & Market Data
Price: $1.87
Daily Change: +$0.02 / 1.07%
Range: $1.82 - $2.07
Market Cap: $22,809,512
Volume: 64,374
Performance Metrics
1 Week: -11.79%
1 Month: -6.03%
3 Months: -46.88%
6 Months: -96.00%
1 Year: -92.67%
YTD: -45.64%
Company Details
Employees: 42
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition. The company was founded in 2017 and is based in Waltham, Massachusetts.